TAAR1 and schizophrenia: To date, two TAAR1 agonists, ralmitaront (F. Hoffmann La-Roche, phase 2, Clinical-Trials.gov identifier: NCT03669640) and ulotaront (SEP-363856, 1-[(7S)-5,7-dihydro-4H-thieno [2,3-c]pyran-7-yl]-N-methylmethanamine, Sunovion Pharmaceuticals, phase 3, described below), are undergoing clinical trials in schizophrenia treatment.